I Vision

I Vision

I Vision is recommended for the treatment and prevention of age-related macular degeneration, diabetic retinopathy, and other degenerative changes of the eye. Key ingredients include lutein, bilberry anthocyanidins, alpha-lipoic acid, and astaxanthin, in addition to the full range of modest-dose B vitamins in their activated forms.
Lutein and Non–Provitamin A Carotenoids
The xanthophylls lutein and zeaxanthin are the main constituents of the yellow macular pigment that accumulates in its highest density in the macula lutea, or “yellow spot.” The macula lutea boasts the highest concentration of these xanthophylls in the human body, and it is thought that they act as antioxidants to blue light exposure there.
The LUXEA (LUtein Xanthophyll Eye Accumulation) study examined the comparative effects of lutein, xeaxanthin, or both on macular pigment optical density (MPOD) in the fovea and parafovea of the retina; this is the area of the eye responsible for sharpest vision known as central vision. Daily doses of 10 and 20 mg of either carotenoid or both were used over a two- to six-month period. Lutein alone or lutein and zeaxanthin both increased MPOD by 15% compared to placebo. While lutein is predominantly deposited in the fovea, zeaxanthin deposition appears to cover a wider retinal area, including the fovea and parafovea.
Although there is less research in general related to natural health products (NHPs) for the prevention of cataracts, diets high in lutein and zeaxanthin have been inversely correlated with the risk of developing cataracts.
Bilberry, Ginkgo biloba
Anthocyanins present in bilberry, Ginkgo biloba, and other herbs act as potent antioxidants that are thought to increase the regeneration of rhodopsin, stabilize collagen fibres, promote collagen biosynthesis, decrease capillary permeability and fragility, and inhibit platelet aggregation and edema.
Two randomized, placebo-controlled trials using 115 mg of bilberry anthocyanins for one and 12 months, respectively, were made on patients with early-stage retinopathy secondary to either diabetes or hypertension. These trials found “reduction of hard exudate” and “significant improvements in the ophthalmoscopic and angiographic patterns in 77–90% of treated patients.”
Gingko improves microcirculation to the retina, and thereby improves tissue oxygenation and clearance of potentially damaging substances; however, Ginkgo should not be given to patients with blood-clotting disorder, hemorrhagic conditions, or on anticoagulation therapy.
Zinc
Zinc protects the retina through antioxidant activity, enhancement of connective tissue synthesis, and its effect as a cofactor for enzymes involved in the chorioretinal complex of the eye. In women, the retina contains the highest concentrations of zinc in the body; while in men it is second only to prostate zinc content. Zinc has been found effective for dry AMD both in combination with other antioxidants (ARED Study) and independently.

Description

Suggested Use

Adults: Take 2 capsules daily with a meal containing oil/fat or as directed by your health-care practitioner. If you are taking other medications, take this product a few hours before or after them.
Duration of use: Consult a health-care practitioner for use beyond 3 months.

Cautions and warnings:

Cautions and warnings: Consult a health-care practitioner prior to use if you are pregnant or breast-feeding, or if you have diabetes or thyroid disorders. Avoid taking if you are hormone-sensitive; have immune disorders; or are on immunosuppressive drugs or anticoagulants or products affecting blood clotting.
Known adverse reactions: Do not use if you are allergic to plants of the Asteraceae/Compositae/Daisy family. Discontinue use and consult a health-care practitioner in case of sweating, paleness, chills, headache, dizziness, and/or confusion, as these may be symptoms of serious low blood sugar.

Ingredients

Each vegetable capsule contains:
Bilberry (Vaccinium myrtillus), 25% anthocyanosides80 mg
ᴅʟ‑alpha-Lipoic acid50 mg
Grape (Vinis vinifera) seed extract, 95% proanthocyanidins50 mg
Lutein (from Tagetes erecta)5.5 mg
Ginkgo bilobaleaf, 24% flavonoid glycosides, 6% terpene lactones25 mg
Multianthocyanidins 20% (fruit blend extract)*25 mg
Haematococcus pluvialis, 1.5% astaxanthin13.33 mg
Tomato extract, 5% lycopene10 mg
Marigold (Tagetes erecta) extract, 20 % zeaxanthin10 mg
Vitamin C (ascorbic acid)170 mg
Vitamin B₁ (thiamine hydrochloride)5 mg
Vitamin B₃ (niacinamide)75 mg
Inositol hexanicotinate, flush-free25 mg
Natural vitamin E (d‑alpha-tocopheryl acid succinate) (30 IU)20.1 mg AT
Vitamin B₂ (riboflavin)25 mg
Vitamin B₂ (riboflavin-5′‑phosphate sodium)5 mg
Vitamin B₆ (pyridoxine hydrochloride)5 mg
Vitamin B₆ (pyridoxal-5′‑phosphate)2 mg
Zinc (from zinc citrate)5 mg
Copper (from copper gluconate)500 mcg
ʟ‑Glutathione25 mg
Selenium (ʟ‑selenomethionine)50 mcg
* Made from a blend of fruit extracts from: Vaccinium myrtillus (extract and fruit powder) and Vitis vinifera (skin and seed).
Other ingredients: Vegetable magnesium stearate and silicon dioxide in a non‑GMO vegetable capsule composed of vegetable carbohydrate gum and purified water.

Key Ingredients in I Vision

IngredientDoseOutcomes
Bilberry, ginkgo60 or 240 mg/d ginkgo extract EGb 761 × 24 weeks99 subjects with dry AMD and impaired vision were given one of two doses of ginkgo extract for 24 weeks; marked improvement in visual acuity was reported. The number of subjects with acuity improvements ≥ 0.2 in the high-dose group was nearly double that in the low-dose group.
Not specifiedGingko resulted in a significant improvement in long-distance acuity seen in patients with AMD receiving ginkgo compared to placebo.
Dose not specified; duration 6 months29 subjects with early diabetic retinopathy: ginkgo resulted in a tendency toward improvement in color vision in the ginkgo group, while there was worsening with placebo.
115 mg anthocyanins × 1–12 monthsTwo trials using 115 mg bilberry anthocyanins for one and 12 months in patients with early retinopathy. There was a “reduction of hard exudate” and “significant improvements in the ophthalmoscopic and angiographic patterns in 77–90% of treated patients”.
alpha-Lipoic acidN/AAdministration with ALA has been shown to improve antioxidant status in patients with AMD, with reduction in MDA, a marker of lipid peroxidation, and increase in SOD activity. Similar findings in patients with preretinopathic diabetes. Another study failed to show an effect on prevention of diabetic retinopathy; more research needed.
400 mg/d
600 mg/d × 2 years
Lutein, zeaxanthin, astaxanthin8 mg zeaxanthin, 9 mg lutein, or both, × 1 yearZVF study (AMD): In the zeaxanthin group, detailed high-contrast visual acuity improved by 1.5 lines, shape discrimination sharpened from 0.97 to 0.57 (p = 0.06), and a larger percentage of zeaxanthin patients experienced clearing of their kinetic visual field central scotomas (p = 0.057). The lutein group was superior in terms of low-contrast visual acuity, contrast sensitivity function, and glare recovery, whereas zeaxanthin showed a trend toward benefit.
10 mg lutein, 1 mg zeaxanthin, 4 mg astaxanthin, and antioxidants/vitamins supplementation formula, or no dietary supplementation × 2 yearsCARMIS study (AMD): Patients in the treated group showed stabilization of visual acuity with significantly (p = 0.003) better VA scores (81.4 ±7.2) compared to the non-treated group (76.8 ±8.9) at two years. An improvement in contrast sensitivity (p = 0.001) and higher visual function scores at 12 and 24 months was also seen in the treatment group (p < 0.001).
Zinc50 mg/d × 6 monthsAfter six months, zinc improved visual acuity (p < 0.0001) and contrast sensitivity (p < 0.0001) in patients with AMD. Macular light flash recovery time also shortened in the ZMC group.
B vitaminsLow-dose B₆, B₁₂, and folic acid × 7+ yearsPrevention of AMD: After over seven years of treatment, the treated group had 34% reduced risk of having AMD and severe AMD: RR for AMD 0.66 (95% CI 0.47 to 0.93). For visually significant AMD, there was a 41% risk reduction, RR 0.59 (95% CI 0.36 to 0.95).